Use

The PanCystPro™ test assists clinicians in the risk stratification of patients diagnosed with pancreatic cystic lesions (PCL). Utilizing a proprietary platform, this test enables the ultrasensitive detection of multiple biomarkers in small volumes of pancreatic cyst fluid. It includes a robust algorithm and a novel protease activity assay, providing better biological insight for clinicians. The test aims to help define low-risk or benign pancreatic cysts, effectively ruling out potential malignancy. This can lead to significant cost savings and peace of mind for patients. The test's high negative predictive value and reduced fluid volume requirements address the needs of gastroenterologists, pancreatic biliary surgeons, and other clinicians managing patients with pancreatic cysts.